Sensus Healthcare, Inc. (NASDAQ:SRTS – Get Rating) saw a significant decrease in short interest in the month of July. As of July 31st, there was short interest totalling 305,000 shares, a decrease of 22.9% from the July 15th total of 395,500 shares. Based on an average trading volume of 232,700 shares, the short-interest ratio is presently 1.3 days. Currently, 2.6% of the company's shares are short sold.
Wall Street Analyst Weigh In
Separately, Maxim Group reissued a "buy" rating and issued a $14.00 target price on shares of Sensus Healthcare in a report on Friday, May 6th.
Get Sensus Healthcare alerts:Insider Buying and Selling
In other news, CEO Joseph C. Sardano sold 36,093 shares of Sensus Healthcare stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $13.97, for a total transaction of $504,219.21. Following the completion of the sale, the chief executive officer now directly owns 1,294,200 shares of the company's stock, valued at approximately $18,079,974. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. In other news, CEO Joseph C. Sardano sold 36,093 shares of the company's stock in a transaction on Tuesday, August 9th. The shares were sold at an average price of $13.97, for a total transaction of $504,219.21. Following the transaction, the chief executive officer now directly owns 1,294,200 shares of the company's stock, valued at approximately $18,079,974. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Joseph C. Sardano sold 28,999 shares of the company's stock in a transaction dated Thursday, August 11th. The shares were sold at an average price of $14.21, for a total transaction of $412,075.79. Following the completion of the sale, the chief executive officer now directly owns 1,171,881 shares in the company, valued at approximately $16,652,429.01. The disclosure for this sale can be found here. Over the last three months, insiders sold 75,114 shares of company stock worth $1,056,202. Company insiders own 16.36% of the company's stock.
Institutional Trading of Sensus Healthcare
Large investors have recently bought and sold shares of the stock. Northwestern Mutual Wealth Management Co. raised its stake in shares of Sensus Healthcare by 83.3% in the fourth quarter. Northwestern Mutual Wealth Management Co. now owns 5,500 shares of the company's stock worth $40,000 after acquiring an additional 2,500 shares during the last quarter. HCR Wealth Advisors acquired a new position in shares of Sensus Healthcare in the fourth quarter valued at approximately $72,000. Acadian Asset Management LLC bought a new position in shares of Sensus Healthcare during the fourth quarter worth about $791,000. Bailard Inc. bought a new stake in Sensus Healthcare during the fourth quarter worth about $249,000. Finally, AE Wealth Management LLC acquired a new position in Sensus Healthcare during the first quarter worth $192,000. 20.49% of the stock is currently owned by institutional investors.Sensus Healthcare Stock Performance
Shares of SRTS stock opened at $14.97 on Friday. Sensus Healthcare has a twelve month low of $3.21 and a twelve month high of $15.25. The company has a market capitalization of $249.70 million, a price-to-earnings ratio of 9.91 and a beta of 0.78. The stock's 50 day simple moving average is $9.63 and its 200 day simple moving average is $9.29.
Sensus Healthcare Company Profile
(Get Rating)
Sensus Healthcare, Inc, a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy (SRT), a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a SRT-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Featured Articles
- Get a free copy of the StockNews.com research report on Sensus Healthcare (SRTS)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.